INPHASE Limited Revenue and Competitors
Estimated Revenue & Valuation
- INPHASE Limited's estimated annual revenue is currently $3.9M per year.
- INPHASE Limited's estimated revenue per employee is $116,000
Employee Data
- INPHASE Limited has 34 Employees.
INPHASE Limited's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Marketing | Reveal Email/Phone |
2 | Chief Technology Officer | Reveal Email/Phone |
3 | Project Manager | Reveal Email/Phone |
4 | Project Manager | Reveal Email/Phone |
5 | Data Migration Specialist | Reveal Email/Phone |
6 | Senior Account and Business Development Manager | Reveal Email/Phone |
7 | Business Development & Client Success Manager | Reveal Email/Phone |
8 | Marketing Copywriter | Reveal Email/Phone |
9 | Senior Business Development Manager | Reveal Email/Phone |
10 | Senior Front End Developer | Reveal Email/Phone |
INPHASE Limited Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $32.4M | 208 | -44% | $176.2M | N/A |
#2 | $34.6M | 217 | N/A | N/A | N/A |
#3 | $9M | 69 | N/A | N/A | N/A |
#4 | $4.2M | 36 | N/A | N/A | N/A |
#5 | $552M | 2417 | -11% | $299.9M | $6.9B |
#6 | $1.2M | 14 | -7% | N/A | N/A |
#7 | $3.7M | 32 | -11% | N/A | N/A |
#8 | $0.3M | 4 | N/A | N/A | N/A |
#9 | $1.5M | 17 | N/A | N/A | N/A |
#10 | $0.9M | 10 | N/A | N/A | N/A |
#11 | $11.9M | 53 | N/A | N/A | N/A |
#12 | $15.7M | 108 | N/A | N/A | N/A |
#13 | $0.9M | 10 | N/A | N/A | N/A |
#14 | $7.7M | 38 | -17% | N/A | N/A |
#15 | $7.4M | 57 | 8% | N/A | N/A |
#16 | $0.4M | 6 | N/A | N/A | N/A |
#17 | $28.7M | 180 | N/A | N/A | N/A |
#18 | $2.1M | 21 | N/A | N/A | N/A |
#19 | $41.6M | 261 | N/A | N/A | N/A |
#20 | $0.9M | 11 | N/A | N/A | N/A |
What Is INPHASE Limited?
N/A
Total Funding
34
Number of Employees
$3.9M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
INPHASE Limited News
2022-04-20 - TRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II ...
... 2.0% of males will develop BED at some point in their lives; current drug treatments to date have demonstrated limited effectiveness.
2022-04-20 - Pfizer to Open First US Sites in Phase 3 Trial of Investigational ...
Duchenne muscular dystrophy is a devastating disease with very limited treatment options, and we believe that gene therapy has the...
2022-04-19 - Paradigm Biopharmaceuticals doses first US subjects in Phase 3 pivotal
trial for treatment of knee osteoarthritis pain
Paradigm Biopharmaceuticals doses first US subjects in Phase 3 pivotal trial for treatment of knee osteoarthritis pain.
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.9M | 34 | N/A | N/A |
#2 | $3.9M | 34 | N/A | N/A |
#3 | $3.9M | 34 | N/A | N/A |
#4 | $6.8M | 34 | N/A | N/A |
#5 | $3.9M | 34 | N/A | N/A |